Evidence map›Paper›PMID 36268860›Full record

ArticleNucleic acids research2023

The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use.

Albert A Antolin, Domenico Sanfelice, Alisa Crisp, Eloy Villasclaras Fernandez, Ioan L Mica, Yi Chen, Ian Collins, Aled Edwards, Susanne Müller, Bissan Al-Lazikani and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Chemoproteomic Profiling ofJournal of medicinal chemistry · 2025
    Article
  10. Article
  11. Development of the Pyrido[2,3-ACS medicinal chemistry letters · 2025
    Article
  12. Phenomics-Based Discovery of Novel Orthosteric Choline Kinase Inhibitors.Angewandte Chemie (International ed. in English) · 2025
    Article
  13. Chemoproteomic Profiling ofbioRxiv : the preprint server for biology · 2025
    Article
  14. Probe my Pathway (PmP): a portal to explore the chemical coverage of the human Reactome.Database : the journal of biological databases and curation · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Albert A AntolinDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.ORCID 0000-0002-1634-9034
Domenico SanfeliceDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.ORCID 0000-0002-8908-0347
Alisa CrispDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.
Eloy Villasclaras FernandezDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.
Ioan L MicaDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.
Yi ChenDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.
Ian CollinsDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.
Aled EdwardsStructural Genomics Consortium, University of Toronto, Toronto, ONM5G 1L7, Canada.
Susanne MüllerInstitute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, 60438, Germany.ORCID 0000-0003-2402-4157
Bissan Al-LazikaniDepartment of Genomics Medicine and the Institute of Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, 77054, USA.ORCID 0000-0003-3367-2519
Paul WorkmanDivision of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG, UK.ORCID 0000-0003-1659-3034
Institute of Cancer Research · GBGoethe University Frankfurt · DEThe University of Texas MD Anderson Cancer Center · USUniversity of Toronto · CA

Funding

Wellcome Trust
6 · The paper itself

Abstract

We describe the Chemical Probes Portal (https://www.chemicalprobes.org/), an expert review-based public resource to empower chemical probe assessment, selection and use. Chemical probes are high-quality small-molecule reagents, often inhibitors, that are important for exploring protein function and biological mechanisms, and for validating targets for drug discovery. The publication, dissemination and use of chemical probes provide an important means to accelerate the functional annotation of proteins, the study of proteins in cell biology, physiology, and disease pathology, and to inform and enable subsequent pioneering drug discovery and development efforts. However, the widespread use of small-molecule compounds that are claimed as chemical probes but are lacking sufficient quality, especially being inadequately selective for the desired target or even broadly promiscuous in behaviour, has resulted in many erroneous conclusions in the biomedical literature. The Chemical Probes Portal was established as a public resource to aid the selection and best-practice use of chemical probes in basic and translational biomedical research. We describe the background, principles and content of the Portal and its technical development, as well as examples of its applications and use. The Chemical Probes Portal is a community resource and we therefore describe how researchers can be involved in its content and development.

Indexed as

Molecular ProbesProteinsDatabases, ChemicalDrug DiscoveryMolecular ProbesProteins

Identifiers

PMID36268860
PMCPMC9825478
OpenAlexW4307036673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.